leisure time -WSS

leisure time

author：explore 2025-09-01 15:09:59 - browse：3677

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Gene editing the human germline: What are the risks?

WSS

SCOTUS questions limit to govt efforts to fight misinformation

The EPA's new lead rule: How one expert crunched the numbers

How to pay for weight loss drugs and save Medicare

Baby aspirin cuts fat buildup in liver disease patients, in small study

Rep. Raul Ruiz on the physician shortage and more

How to pay for weight loss drugs and save Medicare

explore

leisure time

Wikipedia

How one medical school became remarkably diverse

FDA investigates CAR

Moonlake's readout produced a cash windfall. Risks remain

Takeda, Janssen join wearable maker to measure scratching

ChatGPT in medicine: STAT answers readers' burning questions

Health AI adoption puts security, privacy startups on investors' radar

State Dept. review finds Biden bears some blame for Afghanistan failures

Colonoscopy prep: Liquid

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Bluebird, CVS, Contineum

focus

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

U.K. researchers warn about biases in medical devices, algorithms

UnitedHealth’s Optum accused of antitrust violations in California

Stop the failed accountable care organization experiment

How to pay for weight loss drugs and save Medicare

Asbestos, a deadly carcinogen, banned by EPA

entertainment

hotspot

focus

Wikipedia